CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 38 enrolled
Drug / intervention
NRX 194204drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01540071
NCT01540071Phase 2Completed
CompareCT.gov

A Phase II Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer

Io Therapeutics·interventional·Posted Feb 28, 2012·Updated May 14, 2021

In Brief

A Phase 2 clinical trial evaluating NRX 194204 for Castration Resistant Prostate Cancer. Completed, enrolled 38 participants across 1 site.

Detailed Summary

This study is to evaluate the benefits of investigational drug, NRX 194204 in slowing down/stopping/reversing progression of the castration resistant and taxane resistant prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCastration Resistant Prostate Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 28, 2012
Enrollment StartAug 1, 2011
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 14.3 years ago

Interventions

NRX 194204drug

NRX 194204 is an oblong, soft, gelatin capsule and will be taken once a day